Listen on the go
CORRECT!
Next question
touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
HIV, Viral Infections

Helen Koenig, ACTHIV 2021: Current Status and Challenges of HIV Treatment Regimens

Published Online: June 23rd 2021

It was a pleasure to speak with Helen Koenig (MacGregor Infectious Diseases Clinic, Hospital of the University of Pennsylvania, Philadelphia, PA, USA) to discuss the current status challenges of HIV treatment regimens.

The abstract entitled: ‘Antiretroviral Therapy for Treatment and Prevention’ was presented at the ACTHIV Virtual Conference 2021, May 20-22, 2021.

Questions:

  1. Could you tell us the current status of HIV epidemiology? (0:09)
  2. What are the most common clinical presentations of HIV? (2:35)
  3. Could you tell us a little about the aims of HIV therapy? (3:35)

Disclosures: Helen Koenig has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview filmed by Katey Gabrysch.

Filmed in coverage of the ACTHIV Virtual Conference 2021.

Share this Video
Related Videos In Viral Infections
Vaccines, Viral Infections
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Watch Time: 2 mins

Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]

Vaccines, Viral Infections
Developed by Touch
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) prefusion F protein candidate vaccine RSVPreF3 OA – Ongoing phase 3 study results
Watch Time: 4 mins

Respiratory syncytial virus (RSV) presents a significant disease burden in older adults, with no approved vaccines to protect against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the findings from an ongoing phase 3 study investigating vaccine efficacy of the […]

Vaccines, Viral Infections, Bacterial Infections
Developed by Touch
Michael Ison: Highlights from IDWeek 2022
Watch Time: 1 min

In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics. Interviews available in this series: Respiratory syncytial virus (RSV) – Health burden […]

Trending In Viral Infections:

Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Vaccines, Viral Infections
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72